ApprovedMitochondrial / Barth syndrome
Elamipretide
Brand examples:SS-31MTP-131
- Class
- Mitochondrial cardiolipin binder
- Route
- SC injection
- Frequency
- Once daily in approved labeling
- GLP-1 relevance
- No
How it works
Mitochondrial cardiolipin binder (mitochondria-targeted tetrapeptide)
Approved & studied uses
Improving muscle strength in adult and pediatric patients with Barth syndrome weighing at least 30 kg, per US labeling.
Regulatory status
Approved (US, 2025; marketed as FORZINITY). Approval status varies by country.
Safety notes
Prescription-only. Dose and schedule are set by your prescriber; Peptimize does not recommend or adjust them.
Sources
Educational reference only. This page does not provide diagnosis, dosing, titration or treatment recommendations. Peptimize does not recommend or adjust any medication schedule - that is between you and your prescriber.